Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.09 USD
Change Today +0.01 / 0.25%
Volume 2.0M
ARNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6154 Nancy Ridge Drive

San Diego, CA 92121

United States

Phone: 858-453-7200

Fax: 858-453-7210

Arena Pharmaceuticals, Inc. engages in discovering, developing and commercializing drugs to address unmet medical needs. BELVIQ Lorcaserin has been approved for marketing for the indication of weight management, and is being commercialized under the brand name BELVIQ (which is pronounced as BEL-VEEK). BELVIQ was made available by prescription in the United States in 2013 and in South Korea in 2015. There are pending applications for the regulatory approval of BELVIQ for marketing in various additional countries. As of February 16, 2015, the company owned issued patents that cover compositions of matter for the lorcaserin new chemical entity (NCE) and related compounds, and methods of treatment utilizing lorcaserin and related compounds in 69 jurisdictions, including the United States, Japan, China, Germany, France, Italy, the United Kingdom, Spain, Canada, Russia, India, Australia and South Korea, and had applications pending in two other jurisdictions. As of February 16, 2015, the company owned registered trademarks on the use of the name BELVIQ in Class 5 for the sale and marketing of pharmaceutical preparations for weight management, weight loss, the treatment of obesity and the maintenance of weight loss in 125 jurisdictions, including the United States, Japan, China, Germany, France, Italy, United Kingdom, Spain, Russia, India, Australia and South Korea, and had trademark applications pending in 25 other jurisdictions, of which the 2 pharmaceutical markets were Brazil and Canada. The trademark on the name BELVIQ registered by the US Patent and Trademark Office. APD334 Program APD334, an orally available modulator of the S1P1 receptor, is the company’s internally discovered investigational drug candidate intended for the potential treatment of autoimmune diseases, such as multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. As of February 16, 2015, the company owned issued patents that cover compositions of matter for APD334 and related compounds, methods of treatment utilizing APD334 and related compounds, and various salts of APD334 and crystalline forms thereof in 16 jurisdictions, including the United States, Japan, China and Russia, and had applications pending in 8 other jurisdictions, of which the largest pharmaceutical markets were Europe, Brazil, Canada, India, Australia and South Korea. Ralinepag Program Ralinepag, an orally available agonist of the prostacyclin, or IP, receptor, is the company’s internally discovered investigational drug candidate intended for the treatment of pulmonary arterial hypertension, or PAH. In 2014, ralinepag was granted orphan drug status for the treatment of pulmonary arterial hypertension by the US Food and Drug Administration. The company initiated a Phase 2 clinical trial of ralinepag in 2015. As of February 16, 2015, the company owned issued patents covering compositions of matter for ralinepag and related compounds and methods of treatment utilizing ralinepag and related compounds, synthetic routes, and various solid state forms of ralinepag, in 55 jurisdictions, including the United States, Japan, China, Germany, France, Italy, United Kingdom, Spain, Russia and Australia, and had applications pending in other jurisdictions, such as Brazil, Canada, India and South Korea. APD371 Program APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate that the company is exploring for other potential indications, including pain and fibrotic diseases. The company initiated in 2013 a Phase 1 single-ascending dose trial of APD371. As of February 16, 2015, the company owned issued patents covering compositions of matter for APD371 and related compounds in 5 jurisdictions, including the United States and Australia, and had applications pending in 18 other jurisdictions. Temanogrel Program Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases. As of February 16, 2015, the company owned issued patents that cover compositions of matter for temanogrel and related compounds and methods of treatment utilizing temanogrel and related compounds in 85 jurisdictions, including the United States, Japan, China, Germany, France, Italy, the United Kingdom, Spain, Canada, Russia, India, Australia and South Korea, and had applications pending in 14 other jurisdictions. Strategy The key elements of the company’s strategy are as follows: make BELVIQ available to patients for weight management; pursue additional Lorcaserin opportunities; and advance the pipeline and GPCR research. Collaborations The company has collaborations with pharmaceutical companies, including Eisai Inc. and Eisai Co., Ltd. (collectively, Eisai) for most territories worldwide; Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea; CY Biotech Company Limited, or CYB, for Taiwan; and Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary, Abic Marketing Limited, or Teva, for Israel) that provide them rights and responsibilities to seek regulatory approval and commercialize BELVIQ for weight management. The Swiss subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, is responsible for manufacturing and supplying BELVIQ for these companies. Research and Development The company’s research and development expenses included $100.3 million, as of December 31, 2014. Regulations In the United States, the company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Controlled Substances Act and other federal, state or local regulations. Competition The company’s competitors with respect to BELVIQ include Hoffmann-La Roche Inc.; GlaxoSmithKline Consumer Healthcare; VIVUS Inc.; Orexigen Therapeutics, Inc.; and Novo Nordisk. History Arena Pharmaceuticals, Inc. was founded in 1997. The company was incorporated in the state of Delaware in 1997.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNA:US $4.09 USD +0.01

ARNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.78 USD -0.44
Array BioPharma Inc $5.76 USD -0.08
Orexigen Therapeutics Inc $3.91 USD -0.48
Progenics Pharmaceuticals Inc $8.43 USD -0.99
Rigel Pharmaceuticals Inc $2.85 USD -0.08
View Industry Companies
 

Industry Analysis

ARNA

Industry Average

Valuation ARNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.7x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.